The Zoe Report explores the growing demand for regenerative skincare treatments.
“One of the market leaders is Elevai Skincare, which is sold primarily through doctors’ offices and went public on the Nasdaq recently under the ticker symbol ELAB.” – The Zoe Report
The article highlighted Elevai’s patent-pending formulas, including our post-procedure professional treatment and at-home serum.
By combining exosomes with ceramides, vitamin C, glutathione, and peptides, Elevai products target redness, pigmentation, and fine lines while supporting more resilient skin. This recognition reinforces Elevai’s role in driving the future of science-backed, regenerative aesthetics. Read the full article on The Zoe Report.